Integrated post-GWAS, single-cell, and functional analyses prioritize TCTN2 at an osteoarthritis locus associated with innate immunity-related cartilage remodeling - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Comprehensive Integration of Post-GWAS, Single-Cell Insights, and Functional Studies Highlights TCTN2 at an Osteoarthritis Locus Linked to Innate Immune Cartilage Remodeling
Clinical Scorecard: Comprehensive Integration of Post-GWAS, Single-Cell Insights, and Functional Studies Highlights TCTN2 at an Osteoarthritis Locus Linked to Innate Immune Cartilage Remodeling
At a Glance
Category
Detail
Condition
Osteoarthritis
Key Mechanisms
Sterile inflammatory remodeling, regulatory and inflammatory chondrocyte states, tissue-stress biology
Target Population
Individuals with osteoarthritis
Care Setting
Post-genome-wide association study analysis
Key Highlights
Integration of single-cell biology with post-GWAS insights for osteoarthritis
Identification of TCTN2 as a candidate gene within a chr12 susceptibility locus
Use of a Transformer-based prioritization model to rank variants
Modulation of hypertrophic markers by TCTN2 in ATDC5 cells
Evidence of TCTN2 abundance in osteoarthritis cartilage
Guideline-Based Recommendations
Diagnosis
Utilize combined hip and knee osteoarthritis summary statistics for diagnosis
Management
Consider TCTN2 as a target for further functional studies in osteoarthritis
Monitoring & Follow-up
Monitor expression levels of TCTN2 and associated hypertrophic markers
Risks
Evaluate the implications of genetic variants in the context of osteoarthritis progression
Patient & Prescribing Data
Patients diagnosed with osteoarthritis
Potential for targeting TCTN2 in therapeutic strategies
Clinical Best Practices
Integrate genetic insights with functional studies for osteoarthritis management
Utilize single-cell analysis to understand chondrocyte states in osteoarthritis
In a small open-label randomized trial, 2 platelet-rich plasma injections were associated with greater 6-month improvements in pain and function than corticosteroid injection or oral aceclofenac among patients awaiting knee arthroplasty.
